In patients with heart failure, a variety of hemogram parameters are known to be of prognostic significance. This study aimed to investigate which of these parameters is/ are useful in predicting one-year all-cause mortality in patients with acute decompensated heart failure (ADHF).
H eart failure (HF) is among the common causes of mortality and re-hospitalization in developed countries. [1] Despite advances in diagnosis and treatment, heart failure is still associated with high patient mortality. [1] Identification of high-risk patients is important for treatment, and development of new therapeutic modalities. Many studies have been published on predicting prognosis in HF using hemogram parameters. [2] [3] [4] [5] Anemia is known to be a strong and independent predictor of mortality, and red cell distribution width (RDW) has also been associated with mortality, independent of anemia. [3, 4, 6] Further examples include high leukocyte and low relative lymphocyte counts [7] and absolute eosinophil, [5] which have been shown to be predictors of mortality in acute HF. A variety of hematologic parameters is known to be of prognostic significance in patients with heart failure. This study aimed to investigate which of these parameters is/are useful in predicting one-year allcause mortality in patients with acute decompensated heart failure (ADHF).
PATIENTS AND METHODS
Patients hospitalized between September 2012 and March 2013 in our hospital with systolic ADHF were enrolled retrospectively in the study. Systolic HF was defined as a left ventricular ejection fraction (LVEF) ≤40%, as determined by transthoracic echocardiography. Specific eligibility criteria for trial enrolment were as follows: older than 18 years of age; hospitalized for worsening HF; EF ≤40%; and two or more signs or symptoms of fluid overload (e.g., dyspnea, orthopnea, pretibial edema, or jugular venous distension), and discharge alive from the hospital.
The following were excluded: Those patients with malignant diseases; in receipt of medications known to affect complete blood count; with severe renal failure (estimated glomerular filtration rate (eGFR) <15 ml/min/1.73 m 2 ), active hepatic disease, or chronic obstructive pulmonary disease; who had given birth in the last month; who had peripartum cardiomyopathy, chronic inflammatory disorders, or acute infectious disease; and those who had had coronary revascularization/MI or heart surgery within the last month. The end point of the study was all-cause mortality. The study was approved by the institutional ethics committee.
On admission, we assessed each patient's medical history. Each patient completed a questionnaire to obtain data on lifestyle and risk factors. Hypertension (HT) was defined as previous use of antihypertensive medications, a systolic pressure higher than 140 mmHg, or a diastolic pressure higher than 90 mmHg on at least two separate measurements. Diabetes mellitus (DM) was defined as a previous diagnosis if a patient followed a diet or used anti-diabetic medicines, or if a previously untreated patient had a fasting venous blood glucose level of 126 mg/ dL on two occasions. Hypercholesterolemia (HL) was defined as the use of cholesterol-lowering therapy or as total cholesterol of at least 200 mg/dL. Smoking was defined as the current regular use of cigarettes. Anemia was defined as a baseline hemoglobin concentration of less than 13 mg/dL in men and of less than 12 mg/dL in women. [8] The estimated glomerular filtration rate was calculated using the modification of diet in renal disease (MDRD) formula. [9] On admission, venous blood was obtained from all study patients. Hemoglobin (Hbg), hematocrit (Hct) values, RDW values, platelet counts, and white blood cell (WBC), neutrophil, lymphocyte, basophil, monocyte and eosinophil counts were obtained using an automated hematology analyzer (Abbott CellDyn 3700; Abbott Laboratory, Abbott Park, Illinois). Biochemistry measurements were performed by the biochemistry department using standard methods.
Echocardiographic examinations were performed on all patients within 24 hours of admission. All examinations were evaluated via Vivid 5 system (GE healthcare; Wauwatosa, WI) using a 2. We used univariate analysis to quantify the association of variables with all-cause one-year mortality. Variables found to be statistically significant (p<0. 25) in univariate analysis were used in a multivariate logistic regression with backward stepwise method in order to determine the independent prognostic factors of all-cause one year mortality in patients with hospitalized with systolic ADHF. a severe valvular problem; and 13.4% had a coronary artery bypass graft (CABG). Additionally, 14% of the patients had a pacemaker or automatic implantable external defibrillator (PM/AICD) devices. Approximately half of the patients (47.1%) were anemic.
The one-year mortality rate was 29% in the study population. The mean age of the mortality group was higher than that of the survivor group, but the difference was not statistically significant. Clinical features and treatment at discharge of the two groups are shown Table 1 . The present risk factors (HT, DM, HL, AF, CAD, and smoking prevalence) were similar for the two groups. At one year, patients in the mortality
The results are provided as odds ratio (OR) and 95% confidence interval (CI). All statistical analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, Illinois). P value less than 0.05 was considered statistically significant.
RESULTS
119 patients with ADHF (mean-age 67±14 years; 55% male) were included in the study. The one-year mortality rate was 29% in the study population. Of the patients, 51.3% had coronary artery disease (CAD); 63.9% HT; 38.7% DM; 34.5% HL; 26.1% history of cigarette smoking; 32.8% atrial fibrillation (AF); 21% group had significantly higher anemia rates (41.7% and 68.6%, respectively; p=0.007). There were no significant differences between the drug treatments of the two groups, except that angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) therapy was significantly lower in the survivor group (p=0.002).
On analysis of the patients' hemogram parameters, hemoglobin level, platelet, basophil and lymphocyte counts were significantly lower while RDW was significantly higher in dead patients. Neutrophil, monocyte, and eosinophil counts were similar in both groups. Furthermore, lower eGFR and unused ACEI/ ARB were associated with mortality. Glucose, AST, ALT, bilirubin (total, direct, and indirect bilirubin), and uric acid values were similar in both groups. Laboratory values are shown in Table 2 .
Age, presence of hypertension and right ventricular diameter, eGFR, ACE/ARB treatment and hemoglobin levels, RDW values and platelet, leukocyte, lymphocyte, basophil, neutrophil, monocyte, and eosinophil counts were found to have prognostic significance in univariate Cox proportional hazards analysis (Table  3 ). In the multivariate Cox proportional-hazards tality (Fischer's exact test, p=0.043) were significantly higher, while serum sodium levels were significantly lower, compared to patients with good renal function.
DISCUSSION
In the present study, one-year mortality among the ADHF patients was high. In the patients, anemia and renal dysfunction were found to be frequent. Complete blood count parameters, especially hemoglobin level, platelet and lymphocyte count were found to be independent predictors of one-year mortality in the patients.
Some studies have shown that a decrease in platelet count without thrombocytopenia is associated with increased mortality especially in critically ill patients. [10] [11] [12] The exact cause of thrombocytopenia in these patients is unknown. Westenbrink BD et al. demonstrate that CHF patients exhibit a profound and general bone marrow dysfunction, which simultaneously affects multiple haematopoietic lineages, [13] and that NYHA functional class and NT-proBNP were independent predictors of reduced clonogenic potential, indicating that extent of bone marrow dysfunction is related to severity of heart failure. [13] In this study, although LVEF was similar between the two groups, hemogram parameters were lower in the group in which mortality occurred. This situation may be a reflection of hypoperfusion at tissue level. The lower platelet count in the mortal group may be due to bone marrow suppression caused by oxidative stress and inflammation or increased apoptosis. Because there is not more data, we cannot further comment on this model with backward stepwise method, decreased hemoglobin level on admission (p=0.028, hazard ratio [HR] 0.707, 95% CI 0.519-0.963), decreased platelet counts (p=0.023, HR 0.990, 95% CI 0.982-0.999), decreased lymphocyte counts (p=0.045, HR 0.377, 95% CI 0.145-0.978), and unused ACE/ARB treatment at discharge (p=0.020, HR 9.097, 95% CI 1.414-58.550) were found to be independent factors predicting one-year all-cause mortality (Table 4 ).
Correlation analysis revealed that the lymphocyte count had a significant negative correlation with proBNP (r=-0.464, p=0.003) and right ventricle diameter (r=-0.263, p=0.008). RDW positively correlated with proBNP (r=0.315, p=0.050) and creatinine (r=0.258, p=0.005).
In the anemic patients, the number of lymphocytes (p=0.001) and basophils (p=0.001), sodium level (p=0.044), CRP level (p=0.011), RV diameter (p=0.030), and mortality (p=0.002) were significantly higher compared to the non-anemic patients. Low lymphocyte count was associated with low WBC count (p=0.027), low basophil count (p=0.04), low eGFR (p=0.006), high creatinine level (p=0.002), an increase in right ventricle diameter (p=0.026), and high mortality rate (p=0.001) when compared to patients with high lymphocyte counts. There were only 39 patients with proBNP values. Low lymphocyte count was associated with significantly higher proBNP (Z=-2,804, p=0.005). According to the MDRD formula, [9] 32.8% of the patients had eGFR values less than 60 ml/ min/1.73 m 2 . In patients with impaired renal function, RDW values (p=0.011) and occurrence rates of DM (p=0.048), HT (p=0.013), CAD (p=0.019), and mor- Age, presence of hypertension and right ventricular diameter, eGFR, ACE/ARB treatment and hemoglobin levels, RDW values and platelet, leukocyte, lymphocyte, basophil, neutrophil, monocyte, and eosinophil counts were entered into the multivariate logistic regression with the backward stepwise method. ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; eGFR: Estimated glomerular filtration rate; CI: Confidence interval; OR: Odds ratio.
function had approximately twice the mortality rate of those without renal dysfunction (51% versus 26%, respectively). [23] In the present study, patients who had end-stage renal failure or were undergoing hemodialysis were excluded. The incidence of renal dysfunction (eGFR <60 ml/min/1.73 m 2 ) was determined to be 33%. Those with impaired renal function had a significantly higher mortality rate than those with normal and mild renal dysfunction. The progressive deterioration in renal function in HF patients results from multiple mechanisms, including increased renal venous and intra-abdominal pressure, renal hypoperfusion, neurohormonal and inflammatory activation, adenosine release, and drug therapy for HF. [25] In patients with heart failure, increased RDW, independent of anemia, is a marker for predicting mortality. [4] Functional capacity has a prognostic importance for patients with heart failure. In our earlier study, RDW was detected as an independent predictor of functional capacity in patients with chronic HF. [26] In a different study, RDW was determined to be associated with the GRACE risk score in patients with acute coronary syndrome. [27] In patients with HF, increased RDW might be associated with nutritional anemia, inflammation, renal insufficiency, ineffective erythropoiesis, and oxidative stress. [28, 29] In addition, neurohormonal activation seems to be associated with increased erythropoiesis, thus increasing RDW values. [30] In this study, RDW was positively correlated with proBNP and creatinine values. Therefore, the increase in renal dysfunction and neurohormonal activation may contribution to increased RDW values.
In patients with heart failure, anemia or decreased Hgb is often observed for different reasons. A comprehensive review found an anemia incidence of 37.2% in patients with HF that was correlated with increased observed mortality. [3] The prevalence of anemia is higher in HF populations with comorbid kidney disease, advanced age, and more severe symptoms (range, 30% to 61%) when compared to less symptomatic ambulatory populations (range, 4% to 23%). [31] In our study group of patients with anemia, the mean age and serum creatinine value were higher but the eGFR was lower. Most likely due to the small number of patients, the difference was not statistically significant. In the present study, the prevalence of anemia was 47%, according to WHO criteria. A study conducted by Yılmaz et al. reported an incidence of issue. There is a need for comprehensive studies on this topic.
In previous studies, lymphocyte impairment has been found to be common in patients with ADHF, and lymphocyte impairment is known to be associated with increased mortality. [2, [14] [15] [16] Similarly, in the present study, observed mortality was significantly higher in the group with lower lymphocyte counts. Impaired lymphocytes due to splenic congestion is known to be associated with loss of lymphocytes in ADHF patients, and regression of congestion is associated with a return to normal lymphocyte levels. [17] In our study, lymphocyte count was negatively correlated with proBNP and right ventricle diameter, suggesting that impairment may be associated with congestion. In addition, passage of bacterial endotoxins into the bloodstream, [18] long-term increased sympathetic activity, [19] immune activation release of cytokines [20] and apoptotic mechanisms [21] are the causes of decreased lymphocyte counts.
Decreased lymphocyte counts may be associated with the severity of heart failure, and accordingly with increased mortality rates. Pro-inflammatory markers in heart failure (such as TNF-alpha, IL-6, and CRP) are associated with severity of the disease and have been shown to provide more prognostic information than the traditional clinical or other markers. [22] In a study by von Haehling et al., [20] lymphocyte count was found to be significantly correlated with TNF-alpha. Lymphocyte count in patients with heart failure was identified as a possible indication of inflammation. However, in the present study, low lymphocyte count was associated with worse renal function in patients. Thus, renal dysfunction may contribute to increased mortality. Previously, Vaduganathan et al. [14] found that patients with low lymphocyte counts had worse renal function. Additional studies are needed to explain the relationship between renal dysfunction and impaired lymphocytes.
It is known that the use of ACEI and ARB decrease mortality. [1, 23] In the present study, use of ACEI/ARB therapy was found to be associated with a lower mortality rate. Renal dysfunction is common in patients with HF and is associated with increased mortality. [24, 25] A systematic review and meta-analysis showed that more than half of all patients with HF had a degree of renal impairment.
[24] According to this study, patients with moderate-to-advanced renal dys-anemia similar to our study. [32] Patients with signs of congestion, as in our patients, due to hemodilution may have increased the incidence of anemia. In a previous study, HF patients with anemia were very frequently found to have hemodilution. [33] Anemia in patients with heart failure occurs for various reasons. Iron deficiency; renal failure; RAS and sympathetic nervous system activation as a result of increased plasma volume from hemodilution; decreased body mass index; RAS inhibition; secretion of pro-inflammatory cytokines; decreased erythropoietin production due to renal failure and bone marrow dysfunction can cause anemia in patients with HF. [31, 34] In our study, CRP levels in anemic patients were high, suggesting that inflammation may contribute to the development of anemia.
Anemia in patients with HF is known to be a predictor of mortality. The potential mechanisms linking anemia to increased mortality risk in HF have not been characterized, but may be related to changes in ventricular loading conditions and cardiac structure, comorbidity with renal dysfunction, altered neurohormonal activation, or reduced free radical scavenging capacity. Anemia may be a marker of more severe underlying myocardial disease. [6, 7, 31] 
Study limitations
The most important limitation of the study is its retrospective design and the limited number of patients included in the study and hence, larger and multi-centered studies are needed to draw certain conclusions. Even though medications were generally similar after discharge, patients were not monitored for change in medication and doses during the follow-up. Hence, this may constitute a potential confounder for the study results.
In conclusion, decreased hemoglobin level, and lymphocyte and platelet count which can be calculated automatically are especially associated with an increased risk for one-year all-cause mortality in patients admitted with ADHF. Among hematological indices; hemoglobin level, platelet and lymphocyte counts are readily available, useful and inexpensive markers that can be helpful in risk stratification of patients with ADHF.
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